Experiences with
Lymphomas789 public posts
The current status and challenges of CAR-T therapy in CLL
A few members of this group are scheduled for CAR-T and others might find themselves in the same situation in the future so I thought this would be of interest.
"[i]In recent years, novel immunotherapies, including CAR-T cell therapy, have greatly improved treatment options for patients with hematological
Want to take advantage of all our features? Just log in!
or
An indicator in the blood could guide lupus treatment
A clinical trial (called “BEAT-Lupus”) has found that using a combination of two biologic treatments, rituximab and belimumab, may be more effective than using rituximab alone in patients who have not responded well to other treatment. They also found that people with a particular indicator in their
LLS.ORG (USA) WHAT ARE YOUR TOP PRIORITIES FOR 2023?
Dear Advocate,
Whether it’s making sure every patient can afford health insurance that works for them or advancing better treatments, LLS is committed to working tirelessly to advance policies that serve the needs of blood cancer patients and their families.
In 2023 we will continue to work closely
Lymphoma & CLL Highlights Virtual Workshop Jan 19, 2023 03:00 PM in London
Post-ASH 2022 Lymphoma & CLL Highlights Virtual Workshop Time Jan 19, 2023 03:00 PM in London 10:00–13:00 EST/ 15:00–18:00 GMT/ 16:00–19:00 CET
The Post-ASH 2022 Lymphoma & CLL Highlights Virtual Workshop will feature a series of short presentations on lymphoma and chronic lymphocytic leukemia (CLL
ASH 2022 | Key highlights in CLL: clinical trial updates combination therapies novel BTKis Lindsey Roeker and Matthew Davids • 10 Dec 2022
ASH 2022 | Key highlights in CLL: clinical trial updates & the role of combination therapies and novel BTKis
Lindsey Roeker and Matthew Davids • 10 Dec 2022
https://www.vjhemonc.com/video/m1hovnhu05w-key-highlights-in-cll-clinical-trial-updates-the-role-of-combination-therapies-and-novel-btkis/
https